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MaOBJECTIVES This study compared ways of describing treatment effects. The objective was to better explain to clini-
cians and patients what they might expect from a given treatment, not only in terms of relative and absolute risk
reduction, but also in projections of long-term survival.
BACKGROUND The restricted mean survival time (RMST) can be used to estimate of long-term survival, providing a
complementary approach to more conventional metrics (e.g., absolute and relative risk), which may suggest greater
benefits of therapy in high-risk patients compared with low-risk patients.
METHODS Relative and absolute risk, as well as the RMST, were calculated in heart failure with reduced ejection
fraction (HFrEF) trials.
RESULTS As examples, in the RALES trial (more severe HFrEF), the treatment effect metrics for spironolactone versus
placebo on heart failure hospitalization and/or cardiovascular death were a hazard ratio (HR) of 0.67 (95% confidence
interval [CI]: 0.5 to 0.77), number needed to treat ¼ 9 (7 to 14), and age extension of event-free survival þ1.1 years (0.1
to þ 2.3 years). The corresponding metrics for EMPHASIS-HF (eplerenone vs. placebo in less severe HFrEF) were 0.64
(0.54 to 0.75), 14 (1 to 22), and þ2.9 (1.2 to 4.5). In patients in PARADIGM-HF aged younger than 65 years, the metrics
for sacubitril/valsartan versus enalapril were 0.77 (95% CI: 0.68 to 0.88), 23 (15 to 44), and þ1.7 (0.6 to 2.8) years; for
those aged 65 years or older, the metrics were 0.83 (95% CI: 0.73 to 0.94), 29 (17 to 83), and þ0.9 (0.2 to 1.6) years,
which provided evidence of a greater potential life extension in younger patients. Similar observations were found for
lower risk patients.
CONCLUSIONS RMST event-free (and overall) survival estimates provided a complementary means of evaluating the
effect of therapy in relation to age and risk. They also provided a clinically useful metric that should be routinely reported
and used to explain the potential long-term benefits of a given treatment, especially to younger and less symptomatic
patients. (J Am Coll Cardiol HF 2020;8:984–95) © 2020 The Authors. Published by Elsevier on behalf of the American
College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/
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AB BR E V I A T I O N S
AND ACRONYM S
CI = confidence interval
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
NNT = number needed to treat
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
NYHA = New York Heart
Association
RMST = restricted mean
survival time
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985I n randomized controlled trials, the effect oftreatment is usually estimated using a time-to-first-event survival model that compares the
hazard rate of the experimental treatment group (or
groups) and the control group, which produces a haz-
ard ratio (HR) and corresponding 95% confidence in-
terval (CI) (1). By convention, if the upper 95% CI
does not cross unity, the effect of treatment is consid-
ered statistically significant. Although this is the stan-
dard way of reporting the effect of treatment at
medical presentations and in publications, it may
exaggerate the effect of therapy (e.g., if the absolute
risk reduction is small) and may not be readily inter-
pretable by patients in terms of understanding their
survival free of adverse clinical events, including
death (2). Reporting the absolute treatment effect,
as a percent reduction, reduction in event rate, or
number needed to treat (NNT), overcomes the first
of these criticisms (although NNT should be standard-
ized for duration of follow-up). However, metrics of
absolute benefit will generally look better in a high-
risk than in a low-risk population, assuming the pro-
portional risk reduction with the treatment is similar,
at least in the relatively short follow-up that typifies
most trials. Conversely, treatments started earlier in
the course of a disease when patients are at lower
risk (or even in younger patients) may have the po-
tential to lead to greater prolongation of life. Another
assessment of treatment effect that complements HR
and absolute risk reduction or NNT, is the restricted
mean survival time (RMST) (3,4). The RMST can be
interpreted as the mean event-free survival time up
to a pre-specified time point and is equivalent to the
area under the Kaplan-Meier curve from the start of
the study up to that point. Using age at randomiza-
tion instead of time, the RMST approach allows for
estimation of long-term, event-free survival that can
be obtained with a specific intervention compared
with a control group, across different age groups (5).
The RMST provides an estimate of the effect of treat-
ment in terms of time “free of an event,” years of life
gained, or both. Such measures may be more readily
interpretable and quantifiable for patients and clini-
cians. To better understand the use of RMST and
how it compares with other conventional measures
of treatment effect, we analyzed HR, NNT, and
RMST in several large cardiovascular outcome trials.
We also analyzed these metrics in low-risk versus
high-risk subgroups to illustrate how the RMST could
provide relevant information that is less dependent
on the risk of patients, providing a clinically relevant
long-term outlook.METHODS
TRIALS AND ENDPOINTS. The incidence rate
and the effect of treatment illustrated as a
relative risk reduction, absolute event dif-
ference, NNT, and RMST were calculated (see
Statistical Analysis section) in 4 heart failure
(HF) trials: PARADIGM-HF (Angiotensin–
Neprilysin Inhibition versus Enalapril in
Heart Failure), RALES (The Effect of Spi-
ronolactone on Morbidity and Mortality in
Patients with Severe Heart Failure),
EMPHASIS-HF Eplerenone in Patients with
Systolic Heart Failure and Mild Symptoms-
Heart Failure), and DIG (The Effect of
Digoxin on Mortality and Morbidity in Patients with
Heart Failure). A brief description of each of these
trials and their outcomes is provided in the
Supplemental Appendix. In this study, we examined
2 outcomes: 1) the composite of time to first occur-
rence of either HF hospitalization or cardiovascular
death (used to estimate event-free survival); and 2)
all-cause mortality (used to estimate overall sur-
vival). To homogenize the estimates, all follow-up
times were capped at 3 years. The RMST, using age
instead of time, was performed from 60 to 80 years in
all trials, except for the age subgroups in PARADIGM-
HF, in which in patients younger than 65 years, the
age range was 50 to 64 years and in patients aged 65
or older, the age range was 65 to 80 years.These trials were selected because they allowed
comparison of the different means of quantifying the
effect of treatment, as listed previously, and how
patient characteristics could influence these. Because
of its large sample size, we believed that the
PARADIGM-HF trial would give reasonably robust
estimates of the effect of treatment in subgroups (at
least for the composite hospitalization and/or death
outcome). This allowed us to test the hypothesis that
patient risk and patient age would influence potential
gains in event-free survival and overall survival, and
specifically, that these gains would be smaller in
higher risk and older patients compared with that of
lower risk and younger patients. We tested this hy-
pothesis by examining patients in PARADIGM-HF
with a baseline N-terminal pro–B-type natriuretic
peptide (NT-proBNP) level of <1,000 pg/ml (and also
below the median of 1,615 pg/ml) versus $1,000 pg/ml
(and equal or above the median), who were in New
York Heart Association (NYHA) functional class I
TABLE 1 Cox, Event Rates, Number Needed to Treat, Proportional Hazards, and RSMT
CV Death or HFH* Treatment Effect HR (95% CI) p Value
PARADIGM-HF (N ¼ 8,399)
Enalapril (n ¼ 4,212) Sacubitril/Valsartan (n ¼ 4,187)
Events 1,088 (25.8) 893 (20.0) 0.80 (0.73 to 0.88) <0.001
Event-free survival (%) 69.1 (67.4 to 70.7) 73.7 (72.1 to 75.3) þ4.6 <0.001
NNT to benefit 25 (18 to 43) <0.001
Event rates and difference (per 100 patient-yrs) 13.2 (12.5 to 14.1) 10.6 (9.9 to 11.3) to 2.6 (3.7 to 1.6) <0.001
RMST (using follow-up time in days) 895 (884 to 906) 932 (922 to 942) þ37 (23 to 52) <0.001
RMST (using age instead of follow-up time)† 7.3 (6.8 to 7.9) 8.9 (8.2 to 9.5) þ1.5 (0.7 to 2.4) <0.001
All-cause death*
Events 796 (24.3) 683 (21.0) 0.85 (0.77 to 0.94) 0.002
Event-free survival (%) 76.2 (74.6 to 77.7) 79.4 (77.8 to 80.8) þ3.2 0.002
NNT to benefit 43 (26 to 116) 0.002
Event rates and difference (per 100 patient-yrs) 7.6 (7.1 to 8.2) 8.9 (8.3 to 9.6) 1.3 (2.2 to 0.1) 0.002
RMST (using follow-up time in days) 961 (952 to 970) 980 (971 to 988) þ19 (7 to 31) 0.002
RMST (using age instead of follow-up time)† 10.1 (9.5 to 10.8) 10.9 (10.2 to 11.6) 0.8 (0.2 to 1.7) 0.12
RALES (N ¼1,663)
Placebo (n ¼ 841) Spironolactone (n ¼ 822)
Events 512 (60.9) 381 (46.4) 0.67 (0.59 to 0.77) <0.001
Event-free survival (%) 31.9 (27.9 to 36.0) 48.0 (43.2 to 52.6) þ16.1 <0.001
NNT to benefit 9 (7 to 14) <0.001
Event rates and difference (per 100 patient-yrs) 45.4 (41.6 to 49.5) 29.3 (26.5 to 32.5) 16.0 (21.0 to 11.1) <0.001
RMST (using follow-up time in days) 574 (545 to 602) 693 (664 to 722) þ119 (78 to 160) <0.001
RMST (using age instead of follow-up time)† 2.3 (1.7 to 3.0) 3.4 (2.5 to 4.4) 1.1 (0.1 to 2.3) 0.062
All-cause death*
Events 384 (45.7) 284 (34.5) 0.71 (0.61 to 0.83) <0.001
Event-free survival (%) 46.1 (41.5 to 50.5) 60.9 (56.5 to 65.0) þ14.8 <0.001
NNT to benefit 12 (8 to 21) <0.001
Event rates and difference (per 100 patient-yrs) 26.6 (24.1 to 29.4) 18.8 (16.7 to 21.1) 7.8 (11.2 to 4.4) <0.001
RMST (using follow-up time in days) 736 (709 to 762) 812 (786 to 837) þ76 (39 to 113) <0.001
RMST (using age instead of follow-up time)† 4.2 (3.3 to 5.2) 5.8 (4.6 to 7.0) þ1.5 (0.01 to 3.1) 0.049
Continued on the next page
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986and/or II versus class III and/or IV and age younger 65
years versus age 65 years or older. In the subgroups,
we focused on event-free survival, because there was
more statistical power for this outcome than for all-
cause mortality.
The RALES and EMPHASIS-HF trials provided an
indirect comparison of how the effects of a mineral-
ocorticoid receptor antagonist might be modified by
patient risk. RALES was a trial that enrolled a high-
risk advanced HF population (all patients were in
NYHA functional class III and/or IV) who received
suboptimal treatment by today’s standards (e.g., 10%
beta-blocker use). The EMPHASIS-HF trial random-
ized a lower risk, relatively well-treated patient
cohort (all NYHA functional class II; 87% treated with
a beta-blocker).
Because digoxin did not reduce all-cause mortality,
the DIG trial was used to illustrate the effects of
therapy on event-free survival versus overall survival.
All of these trials had similar patient age ranges
and follow-up times.
Ethics approval was obtained for each individual
trial.STATISTICAL ANALYSIS. Cox proportional hazards
models were used to estimate HRs and relative risk
reductions. Event rates and the differences, with the
respective 95% CIs were calculated using the
quadratic approximation to the Poisson log-
likelihood for the log-rate parameter. Event-free
survival was computed using the Kaplan-Meier sur-
vivor function over the full data and compared using
the log-rank test. The NNT to benefit was computed
from the cause-specific cumulative incidence func-
tions. The RSMT is a measure of average event-free
survival from time 0 to a pre-specified time point
(6). We computed the RMST using the within-trial
follow-up time and also used age instead of time
(the age-specific event rates were then estimated).
These estimations were obtained by multiplying the
annual conditional survival probabilities of patients
included in the studies, starting from a specific age,
from projections of the expected duration of event-
free survival (up to a pre-specified time horizon
[tau]), and were non-parametrically estimated by
calculation of the area under the Kaplan-Meier sur-
vival curve (5,7). Subsequently, differences in the
TABLE 1 Continued
CV Death or HFH* Treatment Effect HR (95% CI) p Value
EMPHASIS-HF (N ¼ 2,737)
Placebo (n ¼ 1,371) Eplerenone (n ¼ 1,362)
Events 349 (25.4) 235 (17.3) 0.64 (0.54 to 0.75) <0.001
Event-free survival (%) 64.1 (60.5 to 67.4) 73.9 (70.5 to 77.0) þ9.8 <0.001
NNT to benefit 14 (10 to 22) <0.001
Event rates and difference (per 100 patient-yrs) 16.7 (15.0 to 18.5) 10.5 (9.3 to 12.0) to 6.2 (8.3 to 4.0) <0.001
RMST (using follow-up time in days) 827 (806 to 848) 905 (887 to 923) þ78 (51 to 106) <0.001
RMST (using age instead of follow-up time)† 6.3 (5.3 to 7.4) 9.2 (7.9 to 10.4) þ2.9 (1.2 to 4.5) 0.001
All-cause death*
Events 201 (14.7) 157 (11.5) 0.76 (0.62 to 0.94) 0.010
Event-free survival (%) 77.1 (73.7 to 80.0) 81.8 (78.7 to 84.5) þ4.7 0.010
NNT to benefit 33 (19 to 142) 0.028
Event rates and difference (per 100 patient-yrs) 8.7 (7.6 to 10.0) 6.6 (5.7 to 7.7) 2.1 (3.7 to 0.5) 0.010
RMST (using follow-up time in days) 949 (932 to 966) 978 (963 to 994) þ29 (7 to 52) 0.010
RMST (using age instead of follow-up time)† 8.4 (6.9 to 9.9) 10.2 (8.9 to 11.6) 1.8 (0.2 to 3.8) 0.075
DIG (N ¼ 6,800)
Placebo (n ¼ 3,403) Digoxin (n ¼ 3,397)
Events 1,515 (44.5) 1,335 (39.3) 0.82 (0.76 to 0.88) <0.001
Event free survival (%) 54.2 (52.5 to 55.9) 59.4 (57.7 to 61.0) þ5.2 <0.001
NNT to benefit 20 (15 to 32) <0.001
Event rates and difference (per 100 patient-yrs) 22.0 (20.9 to 23.2) 18.0 (17.1 to 19.0) 4.0 (5.5 to 2.6) <0.001
RMST (using follow-up time in days) 767 (753 to 781) 830 (817 to 843) þ63 (44 to 82) <0.001
RMST (using age instead of follow-up time)† 4.9 (4.5 to 5.4) 5.8 (5.3 to 6.2) þ0.8 (0.2 to 1.5) 0.010
All-cause death*
Events 1,004 (29.5) 1,007 (29.6) 1.00 (0.92 to 1.09) 0.99
Event-free survival (%) 69.8 (68.2 to 71.4) 69.6 (68.0 to 71.1) 0.2 0.99
NNT to benefit NA —
Event rates and difference (per 100 patient-yrs) 12.0 (11.3 to 12.8) 12.1 (11.3 to 12.8) 0.0 (1.0 to 1.0) 0.99
RMST (using follow-up time in days) 916 (905 to 927) 922 (912 to 933) 6 (9 to 21) 0.46
RMST (using age instead of follow-up time)† 7.9 (7.3 to 8.4) 8.0 (7.5 to 8.5) 0.1 (0.6 to 0.9) 0.71
Values are n, n (%), or median (interquartile range). The event-free survival was computed using the Kaplan-Meier survivor function over the full data and compared using the log-rank test. The number
needed to treat (NNT) to benefit was computed from the cause-specific cumulative incidence functions. Median (25th to 75th percentile) follow-up time (days) and age at randomization (years): PARADIGM-
HF: 810 days (564 to 1,069 days) and 64 years (57 to 72 years); EMPHASIS-HF: 639 days (292 to 992 days) and 68 yrs (63 to 74 years); RALES: 714 days (381 to 909 days) and 67 years (59 to 73 years); DIG:
1,152 days (843 to 1,423 days) and 65 years (57 to 71 years). *For consistency, the analysis the follow-up time was capped at 3 years. †For consistency, the RMST used age instead of time and used the same
age range from 60 to 80 years in all the studied trials.
CV ¼ cardiovascular; DIG ¼ Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure; EMPHASIS-HF ¼ Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms; HR ¼ hazard
ratio; PARADIGM-HF ¼ Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure; RALES ¼ Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure;
RMST ¼ restricted mean survival time.
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987estimated duration of event-free survival for patients
treated with active drug and treatment versus those
in a placebo and/or control group were interpreted as
mean years of life gained (or lost). In other words, for
any given age, a survival curve was estimated that
represented the survival probabilities over time for
patients alive at that age and who receiving an active
drug and/or treatment. A corresponding survival
curve was then estimated using data from patients
who were in the placebo and/or control group. From
each survival curve, the average time spent before the
event of interest was estimated by the area under the
survival curve. Because patient age and treatment
assignment were independent of one another due to
randomization, the difference in the areas under thesurvival curve could be interpreted as the effect of
treatment on time spent event free. The key statisti-
cal assumption required to obtain valid long-term
survival projections based on short-term follow-up
data was that a patient’s risk for a given event
depended on age and treatment but not on the
duration of exposure to the treatment (5,8). This
meant that a 79-year-old patient who took sacubitril-
valsartan since the age of 60 years (i.e., 19 years of
treatment exposure) had the same assumed risk of
dying by age 80 years as a 79-year-old patient who
started taking sacubitril-valsartan at age 78 years
(i.e., 1 year of treatment exposure). For consistency,
we assessed the survival data over a maximum
follow-up of 3 years and an age range from 60 to 80
FIGURE 1 RMST Using Age Instead of Time for the Trials Included
Continued on the next page
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989years (tau ¼ 20) in all trials. In the PARADIGM-HF
trial, age projection estimates were also performed
for the previously described subgroups described.
The p values <0.05 were considered statistically sig-
nificant. All analyses were conducted using Stata
version 16 (StataCorp, College Station, Texas).
RESULTS
TRIALS ANALYZED. The overall results for each of
the 4 trials analyzed are shown in Table 1 and Figure 1.
PARAGIGM-HF. Overall, in the PARADIGM-HF trial,
25.8% (13.2 per 100 patient-years) of the patients in the
enalapril group versus 20.0% (10.6 per 100 patient-
years) of the patients in the sacubitril and/or valsar-
tan group experienced the primary composite
outcome (HF hospitalization or cardiovascular death)
at 3 years of follow-up, which gave an HR of 0.80
(95% CI: 0.73 to 0.88), and a NNT of 25 (18 to 43). The
RMST days gained over this follow-up was þ37 (23 to
52) days, and the potential extension of life without an
event was estimated at þ1.5 (0.7 to 2.4) years. The
findings for all-cause death and an increase in overall
survival are shown in Table 1 and Figure 1.
RALES. In the RALES study, 60.9% (45.5 per 100
patient-years) of the patients in the placebo group
versus 46.4% (29.3 per 100 patient-years) of the
patients in the spironolactone group experienced the
primary outcome over 3 years of follow-up, with a
corresponding HR of 0.67 (95% CI: 0.59 to 0.77) and
NNT of 9 (7 to 14). The RMST days gained during
follow-up were þ119 (78 to 160) days and an extension
of event-free survival of þ1.1 (0.1 to þ2.3) years. The
findings for all-cause death and increase in overall
survival are shown in Table 1 and Figure 1.
EMPHASIS-HF. In the EMPHASIS-HF trial, 25.4%
(16.7 per 100 patient-years) of the patients in the
placebo group versus 17.3% (10.5 per 100 patient-
years) of the patients in the eplerenone group
experienced the primary outcome at 3 years ofFIGURE 1 Continued
The restricted mean survival time (RMST) is expressed in potential years
patients at risk represents the number of patients who were enrolled in t
age. A longer potential life extension (area under the Kaplan-Meier curv
likely to have events or dying during follow-up, their potential life extens
Neprilysin Inhibition versus Enalapril in Heart Failure): potential years g
patients treated with sacubitril/valsartan (vs. enalapril), especially for th
hospitalization (HFH). (B) RALES (The Effect of Spironolactone on Morb
population, the potential years gained without event in favor of spirono
within the trial. (C) EMPHASIS-HF (Eplerenone in Patients with Systolic H
in the RALES trial with a treatment effect of eplerenone (vs. placebo) on
within the trial. (D) DIG (The Effect of Digoxin on Mortality and Morbidi
HFH but did not prolong life. ACM ¼ all-cause mortality.follow-up, which gave an HR of 0.64 (95% CI: 0.54
to 0.75) and a NNT of 14 (10 to 22). The RMST days
gained were þ78 (51 to 106) days and an extension
of event-free survival of þ2.9 (1.2 to 4.5) years. The
findings for all-cause death and increase in overall
survival are shown in Table 1 and Figure 1.
DIG. In the DIG trial, 44.5% (22.0 per 100 patient-
years) of the patients in the placebo group versus
39.3% (18.0 per 100 patient-years) of the patients in
the digoxin group experienced the primary outcome
over 3 years of follow-up; the HR was 0.82 (95% CI:
0.76 to 0.88) in favor of digoxin, and the NNT was
20 (15 to 32). Patients who took digoxin gained þ63
(44 to 82) days of follow-up and þ0.8 (0.2 to 1.5)
years of event-free survival. Digoxin did not reduce
all-cause death because there was no increase in
event-free survival (Table 1).
SUBGROUPS IN PARADIGM-HF. The results for each
of the 3 subgroups analyzed are shown in Table 2,
Figure 2, and Supplemental Table 1.
Lower base l ine NT-proBNP level versus h igher
basel ine NT-proBNP leve l . Low NT-proBNP was
defined as <1,000 pg/ml and high NT-proBNP
as $1,000 pg/ml (Table 2). The analysis was also
performed using the trial median NT-pro BNP of 1, 615
pg/ml (Supplemental Table 1).
Among patients with a NT-pro BNP <1,000 pg/ml,
the levels were 680 pg/ml (quartile 1 to quartile 3 [Q1
to Q3]: 527 to 827 pg/ml), and the mean  SD age was
61.8  11.2 years. The primary outcome was experi-
enced in 16.8% (7.6 per 100 patient-years) of those in
the enalapril group and 12.6% (5.6 per 100 patient-
years) in the sacubitril/valsartan group over 3 years
of follow-up, which gave a HR of 0.73 (95% CI: 0.59 to
0.91), a NNT of 27 (16 to 83), and þ26 (6 to 47) days of
RSMT gained during follow-up. The estimated
extension of event-free survival was þ2.3 (0.6 to 4.0)
years.gained without an event from 60 to 80 years of age. The number of
he trial(s) in whom the event of interest had not occurred at a given
e) was observed for patients at lower risk. Because they were less
ion was improved with treatment. (A) PARADIGM-HF (Angiotensin–
ained without event were observed across all the age groups in
e composite outcome of cardiovascular death (CVD) or heart failure
idity and Mortality in Patients with Severe Heart Failure): high-risk
lactone (vs. placebo) were observed especially at younger ages
eart Failure and Mild Symptoms): a lower risk population than that
life extension that was observed across all the ages (60 to 80 years)
ty in Patients with Heart Failure): digoxin extended the time free of
TABLE 2 Treatment Effect Estimates in PARADIGM-HF Subgroups (N ¼ 8,399)
CV death or HFH* Enalapril (n ¼ 4,212) Sacubitril/Valsartan (n ¼ 4,187) Treatment Effect HR (95% CI) p Value
NT-proBNP <1,000 pg/ml (N ¼ 2,481) 1,262 1,219
Events 212 (16.8) 153 (12.6) 0.73 (0.59 to 0.91) 0.004
Event-free survival (%) 79.2 (76.2 to 81.8) 84.5 (82.2 to 87.2) þ5.3 0.004
NNT to benefit 27 (16 to 83) 0.004
Event rates and difference (per 100 patient-yrs) 7.6 (6.6 to 8.7) 5.6 (4.7 to 6.5) to 2.0 (3.4 to 0.7) 0.004
RMST (using follow-up time in days) 979 (964 to 994) 1,005 (991 to 1,019) þ26 (6 to 47) 0.013
RMST (using age instead of follow-up time)† 9.9 (8.7 to 11.0) 12.2 (10.9 to 13.5) þ2.3 (0.6 to 4.0) 0.009
NT-proBNP $1,000 pg/ml) (N ¼ 5,904) 2,941 2,963
Events 902 (30.7) 760 (25.7) 0.81 (0.73 to 0.89) <0.001
Event-free survival (%) 64.8 (62.7 to 66.8) 69.0 (66.8 to 71.0) þ4.2 <0.001
NNT to benefit 24 (16 to 44) <0.001
Event rates and difference (per 100 patient-yrs) 16.0 (15.0 to 17.1) 12.9 (12.0 to 13.9) 3.1 (4.5 to 1.7) <0.001
RMST (using follow-up time in days) 849 (835 to 862) 891 (879 to 903) þ42 (24 to 61) <0.001
RMST (using age instead of follow-up time)† 6.4 (5.7 to 7.0) 7.8 (7.0 to 8.5) þ1.4 (0.4 to 2.4) 0.006
NYHA functional class I/II (N ¼ 5,057) 2,511 2,546
Events 759 (30.2) 597 (23.4) 0.75 (0.68 to 0.84) <0.001
Event-free survival (%) 70.8 (68.8 to 72.6) 76.6 (74.7 to 78.3) þ5.8 <0.001
NNT to benefit 21 (15 to 34) <0.001
Event rates and difference (per 100 patient-yrs) 12.2 (11.4 to 13.1) 9.2 (8.5 to 9.9) 3.0 (4.1 to 1.8) <0.001
RMST (using follow-up time in days) 910 (898 to 922) 952 (942 to 963) þ42 (26 to 58) <0.001
RMST (using age instead of follow-up time)† 7.8 (7.1 to 8.5) 9.6 (8.9 to 10.4) þ1.9 (0.8 to 2.9) <0.001
NYHA functional class III/IV (N ¼ 1,695) 892 803
Events 329 (36.9) 295 (36.7) 0.93 (0.80 to 1.09) 0.40
Event-free survival (%) 63.9 (60.3 to 67.2) 64.7 (61.1 to 68.2) 0.8 0.40
NNT to benefit NA -
Event rates and difference (per 100 patient-yrs) 16.2 (14.9 to 18.5) 15.5 (13.7 to 17.3) 1.1 (3.6 to 1.4) 0.36
RMST (using follow-up time in days) 828 (806 to 850) 847 (825 to 869) 19 (12 to 49) 0.24
RMST (using age instead of follow-up time)† 6.2 (5.2 to 7.3) 6.8 (5.6 to 8.0) 0.6 (1.0 to 2.2) 0.48
Age <65 yrs (N ¼ 4,279) 2,168 2,111
Events 545 (25.1) 422 (20.0) 0.77 (0.68 to 0.88) <0.001
Event-free survival (%) 70.0 (67.6 to 72.2) 75.6 (73.3 to 77.8) þ5.6 <0.001
NNT to benefit 23 (15 to 44) <0.001
Event rates and difference (per 100 patient-yrs) 13.0 (11.9 to 14.1) 10.0 (9.1 to 11.0) 3.0 (4.4 to 1.5) <0.001
RMST (using follow-up time in days) 889 (874 to 904) 930 (916 to 943) þ40 (21 to 61) <0.001
RMST (using age instead of follow-up time)† 6.0 (5.2 to 6.7) 7.7 (6.9 to 8.4) þ1.7 (0.6 to 2.8) 0.003
Age $65 yrs (N ¼ 4,120) 2,044 2,076
Events 543 (26.6) 471 (22.7) 0.83 (0.73 to 0.94) 0.003
Event-free survival (%) 68.2 (65.7 to 70.5) 72.0 (69.5 to 74.2) þ3.8 0.001
NNT to benefit 29 (17 to 83) 0.003
Event rates and difference (per 100 patient-yrs) 13.5 (12.4 to 14.7) 11.2 (10.2 to 12.2) 2.3 (3.9 to 0.1) 0.001
RMST (using follow-up time in days) 892 (877 to 907) 925 (912 to 940) þ33 (13 to 54) 0.002
RMST (using age instead of follow-up time)† 6.9 (6.4 to 7.3) 7.8 (7.3 to 8.3) þ0.9 (0.2 to 1.6) 0.010
Values are n, n (%), or median (interquartile range). The event-free survival was computed using the Kaplan-Meier survivor function over the full data and compared using the log-rank test. The number
needed to treat (NNT) to benefit was computed from the cause-specific cumulative incidence functions. *For consistency, the analysis using follow-up time was capped at 3 years. †For consistency, the
restricted mean survival time (RMST) using age instead of time used the same age range from 60 to 80 years in the studied subgroups of the PARADIGM-HF (Angiotensin–Neprilysin Inhibition versus Enalapril
in Heart Failure) trial, except for the age subgroups in which in patients younger than 65 years, the age range was 50 to 64 years and in patients age 65 or older, the age range was 65 to 80 years
(i.e., tau ¼15). This metric is expressed in years.
CI ¼ confidence interval; CVD ¼ cardiovascular death; HFH ¼ hospitalization for heart failure; HR ¼ hazard ratio; NA ¼ not applicable because the absolute risk reduction is not statistically significant;
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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990Among patients with a NT-proBNP $1,000 pg/ml,
the levels were 2,330 pg/ml (Q1 to Q3: 1,512 to 4,361
pg/ml), and mean age was 64.6  11.4 years. Among
these patients, the event rates were higher (30.7%;
16.0 per 100 patient-years in the enalapril group vs.
25.7%; 12.9 per 100 patient-years in the sacubitril/
valsartan group), and the relative risk reduction wassmaller (HR: 0.81; 95% CI: 0.73 to 0.89), but there was
a lower NNT of 24 (16 to 44). RMST days gained dur-
ing the follow-up were similar þ42 (24 to 61) days,
and the estimated extension of event-free survival
was smaller, at þ1.4 (0.4 to 2.4) years.
Among patients with NT-proBNP below the
median, the levels were 888 pg/ml (Q1 to Q3: 642 to
FIGURE 2 PARADIGM-HF: RMST Using Age Instead of Time in Subgroups Reflecting Patient Risk and Age
The number of patients at risk represents the number of patients who were enrolled in the trial(s) in whom the event of interest had not
occurred at a given age. A longer potential life extension (area under the Kaplan-Meier curve) was observed for patients with lower N-
terminal pro–B-type natriuretic peptide (NT-proBNP) levels, who were in New York Heart Association (NYHA) functional class I and/or II, and
were younger than 65 years, which suggested that the long-term benefits of sacubitril/valsartan were particularly important in less
symptomatic and younger patients (i.e., patients with lower risk). Abbreviations as in Figure 1.
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9921,201 pg/ml), and the mean age was 62.8  11.1 years.
These patients experienced the primary outcome in
18.2% (8.8 per 100 patient-years) of those in the ena-
lapril group and in 13.9% (6.5 per 100 patient-years) in
the sacubitril/valsartan group over 3 years of follow-
up, which gave an HR of 0.74 (95% CI: 0.63 to 0.86), a
NNT of 24 (16 to 48), and þ34 (17 to 51) days of RSMT
gained during follow-up. The estimated extension of
event-free survival was þ2.4 (1.1 to 3.8) years.
Among patients with a NT-pro BNP above the me-
dian, the levels (Q1, Q3) were 3,231 (2,186, 5,593) pg/
ml; and mean (SD) age was 64.8 (11.6) years. Among
these individuals, the event rates were higher (33.4%,
18.4 per 100 patient-years in the enalapril group vs.
28.7%, 15.2 per 100 patient-years in the sacubitril/
valsartan group). The relative risk reduction was
smaller (HR: 0.83; 95% CI: 0.75 to 0.93), but there was
a similar NNT of 25 (16 to 61). RMST days gained
during the follow-up were similar at þ41 (18 to 63)
days, and the estimated extension of event-free sur-
vival was smaller 0.9 (0.1 to 2.0) years.
Pat ients in NYHA funct iona l c lass I / I I versus
NYHA funct ional c lass I I I / IV . Among individuals
in NYHA functional class I and/or II (mean age: 63.1 
11.5 years), 30.2% (12.2 per 100 patient-years) of those
in the enalapril group and 23.4% (9.2 per 100 patient-
years) of patients in the sacubitril/valsartan group
experienced the primary outcome over 3 years of
follow-up, which gave an HR of 0.75 (95% CI: 0.68 to
0.84), a NNT of 21 (15 to 34), and þ42 (26 to 58) days of
RSMT gained during follow-up. The estimated
extension of event-free survival was þ1.9 (0.8 to 2.9)
years.
In patients in NYHA functional class III and/or IV
(mean age: 66.0  10.6 years), the event rates were
higher (36.9%, 16.2 per 100 patient-years in the ena-
lapril group vs 36.7%, 15.5 per 100 patient-years in the
sacubitril/valsartan group), and the relative risk
reduction was smaller (HR: 0.93; 95% CI: 0.80 to
1.09). The RMST days gained during the follow-up
were 19 (12 to 49) days, and the estimated exten-
sion of event-free survival was 0.6 (1.0 to 2.2) years,
both of which were nonsignificant and of smaller
magnitude than in the NYHA functional class I and/or
II group.
YOUNGER PATIENTS VERSUS OLDER PATIENTS. Among
individuals aged younger than 65 years (mean age:
54.9  8.0 years), 25.1% (13.0 per 100 patient-years) of
those in the enalapril group and 20.0% (10.0 per 100
patient-years) of patients in the sacubitril/valsartan
group experienced the primary outcome over 3 years
of follow-up, which gave an HR of 0.77 (95% CI: 0.68
to 0.88), a NNT of 23 (15 to 44) and þ40 (21 to 61 days)of RSMT gained during follow-up. The estimated
extension of event-free survival was þ1.7 (0.6 to
2.8) years.
In patients aged 65 years or older (mean age: 73.0 
5.7 years), the event rates were higher (26.6%; 13.5 per
100 patient-years in the enalapril group vs. 22.7%; 11.2
per 100 patient-years in the sacubitril/valsartan
group), the relative risk reduction was smaller (HR:
0.83; 95%CI: 0.73 to 0.94), and theNNTwas larger at 29
(17 to 83). RMST days gained during the follow-up was
similarþ33 (13 to 54) days, and the estimated extension
of event-free survival was smaller þ0.9 (0.2 to 1.6)
years.
The summary of the main characteristics of the
RMST compared with absolute and relative risk met-
rics is provided in the Central Illustration.
DISCUSSION
In this study, we showed how analysis of RMST can
complement conventional ways of describing the
benefit of treatment in clinical trials, which expanded
on our previous descriptions of using this metric (5,9).
We chose several exemplar trials to illustrate the
strengths and limitations of the different ways of
describing the effect of treatment. The absolute
treatment benefit, whether expressed as a percent
reduction, rate reduction, or NNT, was greatly influ-
enced by the absolute risk of the patients studied,
assuming the proportional risk reduction with treat-
ment was similar across all populations. The absolute
risk also reflected use of effective background therapy.
We illustrated this in 2 ways. First, by comparison of
patients in the PARADIGM-HF trial with higher NT-
proBNP versus lower NT-proBNP (or NYHA
functional class I and II vs NYHA functional class III
and IV), in which patients with less severe or advanced
HF had 2 to 3 times longer event-free survival than
patients with more severe or advanced HF. Compari-
son of overall survival in the RALES and EMPHASIS-HF
trials supported these findings, with the sicker, less
well-treated patients in the RALES study having a NNT
at 3 years to prevent 1 death of only 12 patients,
compared with 33 patients in the EMPHASIS-HF trial,
despite similar relative risk reductions of 0.71 (0.61 to
0.83) in the RALES study and 0.76 (0.62 to 0.94) in the
EMPHASIS-HF trial. Yet, the potential years of life
gained in the RALES study was 1.5 years (0.01 to 3.1
years) compared with 1.8 years (0.2 to 3.8 years) in the
EMPHASIS-HF trial, with an even bigger difference in
event-free survival: 1.1 years (0.1 to 2.3 years) versus
2.9 years (1.2 to 4.5 years). This was probably because
the ability to extend the duration of life in very sick
patients, with any treatment, was limited. This was
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Ferreira, J.P. et al. J Am Coll Cardiol HF. 2020;8(12):984–95.
The restricted mean survival time (RMST) using age instead of time allows the estimation of long-term, event-free survival, which is a clinically meaningful metric for
both the clinicians and patients. The projections of long-term survival may be particularly useful for explaining the potential long-term benefits of treatments to less
symptomatic/lower risk patients. In contrast, the absolute risk reduction may be less pronounced in lower risk patients, which may discourage them from taking
additional therapies that could substantially increase the long-term event-free time. DIG ¼ The Effect of Digoxin on Mortality and Morbidity in Patients with
Heart Failure; EMPHASIS-HF ¼ Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms; Eple. ¼ eplerenone; HF ¼ heart failure; HR ¼ hazard ratio;
PARADIGM-HF ¼ Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure; RALES ¼ The Effect of Spironolactone on Morbidity and Mortality in Patients with
Severe Heart Failure Sac./Val. ¼ sacubitril/valsartan; Spiro. ¼ spironolactone.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This
work provided relevant information on the use of
RMST, using follow-up time and age instead of time as
a complement to the treatment effect estimates in HF
trials. RMST provided an additional means of evalu-
ating the effect of therapy in relation to age and risk,
and provided a clinically useful metric that should be
routinely reported and used to explain the potential
long-term benefits of a given treatment, especially to
younger and less symptomatic patients who might be
more reluctant to adhere to a treatment for life.
TRANSLATIONAL OUTLOOK: This work might
help change the landscape of how trial results are
presented and help in the discussions with payers,
clinicians, and patients.
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994also the case in older patients compared with younger
patients. The latter point was illustrated by our anal-
ysis of the PARADIGM-HF trial, which examined
extension of life over a 15-year follow-up period. In
patients who started treatment before the age of 65
years, the gain in event-free survival was 1.7 years,
compared with 0.9 years in those who started treat-
ment at aged 65 years or older. We previously illus-
trated this for other ages in the PARADIGM-HF and
EMPHASIS-HF studies (5,9).
Consequently, age and risk (which, in part, is
related to age) are both important considerations
when evaluating treatment benefit. In an extreme
case, a treatment might postpone or prevent many
premature events in the short term (i.e., the duration
of a typical trial) but lead to relatively little life-
extension in a very sick, older adult population.
Conversely, the same treatment could result in a much
more modest, short-term absolute risk reduction in
less sick, younger patients, yet lead to a substantial
extension in length of life. In both trials, the relative
risk reduction might be the same. These examples
illustrated how RMST might be useful in discussions
with payers about the use of treatments in younger or
lower risk patients in whom conventional metrics of
treatment benefit (absolute risk reduction, NNT)
might not look favorable. They might also be useful in
patients whomight be reluctant to consider embarking
on treatment at a young age (and potentially facing
many years of treatment) or adding another treatment
to several that they might already be taking.
This is not to diminish the importance of delaying
or preventing nonfatal events and prolonging event-
free survival, which is possible even with treat-
ments that do not alter all-cause mortality. This was
illustrated by our analysis of the DIG trial, in which
the gain in event-free survival was due to a reduction
in hospitalizations for HF but not mortality.
STUDY LIMITATIONS. These were post hoc analyses.
Our findings were derived from trial data, and their
generalizability to a real-world population might be
limited. Subgroup analyses might not always provide
robust estimates of the true effect of a treatment.
Although we used NT-proBNP and NYHA functional
class as proxies for risk, risk was a multivariable
construct. The use of the RMST with age instead of
follow-up time required a wide range of age in the
population analyzed and a sufficiently large number
of events across the age spectrum to provide rela-
tively stable age-specific risk estimates. The pro-
posed method made some major statistical
assumptions and was therefore only suitable for the
exploratory analyses in this study. The key
assumption was that although a patient’s risk of anevent was related to their age and treatment group,
it was not related to the length of time they spent in
the study. Therefore, this methodology would not be
suitable in studies in which the event rate was
substantially elevated in the period shortly after
randomization (e.g., in surgical trials or trials with a
large variation in underlying patient risk). The pro-
posed method would also be unsuitable in the
presence of a competing risk (e.g., non-
cardiovascular death) that was either frequent or
imbalanced between treatment groups.
CONCLUSIONS
RMST event-free (and overall) survival estimates
provide a complementary means of evaluating the
effect of therapy in relation to age and risk. It pro-
vides a clinically useful metric that should be
routinely reported and used to explain the potential
long-term benefits of a given treatment, especially to
younger and less symptomatic patients who might be
more reluctant to adhere to a treatment for life.
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